(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker. The figure includes up to $1...
网页链接(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker. The figure includes up to $1...
网页链接
精彩评论